<p><strong>🎤Dr. Steven Weinman </strong>(Associate Professor of Chemical and Biological Engineering at the University of Alabama)</p><p><strong>Steven shares his journey from chemical engineering student to membrane researcher, and explains how membranes are used not only for water purification, but also for sample preparation, pre-treatment, and concentration in analytical workflows. The conversation dives deep into PFAS removal, nanofiltration vs. reverse osmosis, and how chromatography and mass spectrometry are essential for validating membrane performance.</strong></p><h4><strong>Key topics discussed include:</strong></h4><ul><li>How membranes function as separation and concentration tools</li><li>Nanofiltration vs. reverse osmosis for salts and PFAS</li><li>The role of chromatography (LC-MS, GC-MS, ion chromatography) in verifying contaminant removal</li><li>Challenges in scaling academic separation technologies to industry</li><li>Sustainability in membrane manufacturing and PFAS-related regulations</li><li>Training students to balance fundamental science with real-world applications</li></ul><p>Whether you work in environmental analysis, chromatography, mass spectrometry, water quality, or separation science, this episode provides valuable insight into how different separation technologies complement each other—and where the field is heading next.</p><h3><strong>Video Transcription</strong></h3><h4><strong>Introduction</strong></h4><p>Membrane-based separations have become a central part of modern water treatment and resource recovery, offering energy-efficient routes for purification, concentration, and selective contaminant removal. In this discussion, Stephen reflects on his path into chemical engineering and membrane science, then explores how membrane technologies fit within broader separation science, how selectivity is designed into membrane systems, and why translation from academic research to industrial deployment remains challenging.</p><p>His perspective spans both fundamental membrane science and practical engineering, with particular emphasis on water treatment, contaminant removal, sustainable membrane manufacturing, and the realities of research funding and scale-up.</p><h4><strong>From Chemical Engineering to Membrane Research</strong></h4><p>Stephen’s route into membrane science began indirectly. Although his early interests were far removed from chemical engineering, he found himself drawn to chemistry and mathematics during high school, which led him to pursue chemical engineering at the University of Kentucky. His first direct exposure to research came through a cooperative placement with a university-affiliated research institute, where he worked on ceramic membrane systems for coal-fired power plant applications.</p><p>That experience introduced him to bench-scale research, scientific literature, and technical presentation, while also clarifying that research was more appealing to him than traditional industrial internships. He subsequently joined the laboratory of a membrane scientist at the University of Kentucky, where he began working on polymeric membranes for water treatment. This set the direction for graduate study, ultimately leading him to Clemson University, where he pursued PhD research on antifouling membranes using surface chemistry and patterning approaches.</p><p>Although his original career plan had been to join a membrane company after graduate school, that trajectory changed late in his doctoral training. Encouragement from colleagues and family led him to consider academia, where he could define his own research questions and continue mentoring students. He joined the University of Alabama immediately after graduation and has since built a research program focused on water treatment problems using membranes, solvents, and polymer-based sorbents.</p><h4><strong>Membrane Separation in the Broader Context of Analytical and Separation Science</strong></h4><p>Stephen frames membranes as one tool within a broader separation science landscape. Their role depends entirely on the feed composition, the desired product stream, and the ultimate process objective. In some cases, membranes are ideal for concentrating target species or dewatering mixtures. In others, they serve as pretreatment tools, removing particulates, unwanted macromolecules, or selected contaminants before downstream analytical or processing steps.</p><p>This logic parallels broader analytical workflows, including chromatographic and spectrometric methods, where sample preparation and matrix simplification are often critical. Even very routine laboratory operations, such as syringe filtration, rely on membrane principles. In that sense, membranes are already embedded in many analytical workflows, even when they are not the primary focus.</p><p>He also points out that certain membrane-based systems can begin to overlap conceptually with chromatographic approaches, particularly in applications such as protein and biologics purification, where membrane adsorbers and membrane chromatography can provide high-throughput alternatives to conventional packed columns.</p><h4><strong>Membrane Selectivity: Matching the Separation to the Problem</strong></h4><p>A recurring theme in the discussion is that membrane selection is application-specific. The right membrane depends on what must be retained, what must pass through, and whether the goal is purification, concentration, or fractionation.</p><p>Stephen distinguishes between several broad classes of membranes. Microfiltration and ultrafiltration operate largely through size exclusion, although charge effects may still contribute. These are useful when target species differ sufficiently in size. At the more selective end, nanofiltration and reverse osmosis are used for salts, small molecules, and persistent contaminants. Nanofiltration is often well suited for rejecting divalent ions while allowing more monovalent ions to pass, whereas reverse osmosis is required when more complete salt rejection is necessary.</p><p>For contaminants such as PFAS, nanofiltration can reject a substantial fraction of compounds, although shorter-chain and smaller species are more difficult. Reverse osmosis offers broader rejection, but also with higher pressure requirements. This highlights a central engineering tradeoff: tighter selectivity generally requires higher energy input.</p><p>He emphasizes that membrane systems always produce at least two streams: a permeate stream and a retentate or concentrate stream. Designing the separation therefore requires consideration not only of product quality but also of what happens to the reject stream. In many cases this becomes a waste stream; in others, it may represent a concentrated resource that requires additional processing or recovery.</p><h4><strong>Advances in Membrane Materials and System Performance</strong></h4><p>Over the course of more than a decade in membrane science, Stephen has seen important improvements in commercial membrane technology, particularly in the area of lower-pressure reverse osmosis. Traditionally, reverse osmosis has required higher operating pressures than nanofiltration. Recent developments have reduced that burden, allowing similar water productivity at lower pressure or smaller membrane area for a given throughput.</p><p>These advances matter because they reduce either energy demand or plant footprint, both of which are significant in industrial and municipal treatment systems. While pressure recovery devices have also improved overall system efficiency, he distinguishes those engineering gains from the membrane materials themselves.</p><p>On the research side, he highlights the emergence of membrane adsorbers and related hybrid technologies that can support faster, higher-throughput separations than conventional column-based workflows. These have gained particular traction in the purification of proteins and biologics, although he suggests that similar concepts may become increasingly relevant in water treatment and selective ion or molecule recovery.</p><h4><strong>Chromatography and Mass Spectrometry as Tools for Membrane Research</strong></h4><p>Although many membrane processes target relatively simple separations such as desalination, more advanced membrane studies increasingly rely on analytical chemistry for validation and mechanistic insight. Stephen describes how chromatographic and mass spectrometric methods are essential when the separation targets are more complex than salts.</p><p>His group uses ion chromatography for specific ionic analytes, as well as GC-MS and electrospray-based methods for organic compounds and degradation products. One recent example involved a biocatalytic membrane designed to degrade phthalates, where GC-MS was used to detect both the parent phthalate and the resulting breakdown products. In such cases, analytical methods are not merely confirmatory; they are central to demonstrating that the membrane or membrane-coupled system is functioning as intended.</p><p>This reinforces the idea that membrane science and analytical chemistry are closely linked in emerging applications, especially where contaminant transformation, trace-level detection, or selective removal must be verified rigorously.</p><h4><strong>The Difficulty of Scale-Up</strong></h4><p>One of the most substantial barriers in membrane research is translation from academic bench-scale work to industrial or municipal scale. Stephen identifies two major constraints: time and cost.</p><p>Academic demonstrations often rely on reaction steps, modification procedures, or fabrication methods that work well on the laboratory scale but are far too slow for industrial practice. A protocol that takes hours or days in a research setting is rarely attractive to a manufacturer seeking cycle times measured in seconds or minutes. Likewise, materials that seem acceptable at gram scale may be prohibitively expensive at production scale, although the reverse may also be true if bulk pricing is favorable.</p><p>The more fundamental challenge is that academic research is not usually funded to perform pilot-scale development. The mission is often centered on fundamental science and student training, not industrial process engineering. Moving from proof-of-concept to deployable technology requires time, equipment, space, and funding that many university laboratories simply do not have.</p><p>For this reason, Stephen sees academia’s main role as laying the conceptual and technical groundwork. If a technology shows promise, the ideal outcome is that an industrial partner, start-up, or other translational pathway takes it further. In some cases, research can be designed from the start with scalability in mind. He cites current work on reverse osmosis membrane additives as an example, where the goal is not to reinvent membrane fabrication but to introduce a change that could plausibly fit existing manufacturing workflows.</p><h4><strong>Sustainability and Greener Membrane Science</strong></h4><p>Membrane processes themselves are often relatively energy efficient compared with thermal separations, but Stephen notes that membrane manufacturing still has significant room for improvement. Conventional membrane fabrication often relies on hazardous, petroleum-derived solvents, and one area of active research is the substitution of greener or bio-based alternatives.</p><p>Another direction is the use of waste plastics as feedstock for membrane fabrication. The rationale is pragmatic: if such plastics are already present in the environment, converting them into membranes may extend their useful lifetime and partially offset their environmental burden. More biodegradable or less petroleum-dependent polymers are also attractive, but they must still meet cost and performance requirements.</p><p>He also discusses an important regulatory issue involving polyvinylidene fluoride (PVDF), one of the most widely used membrane polymers. Debate over whether it should be treated as a PFAS-related material could have major implications for membrane manufacturing and use. From his perspective, classifying PVDF in that way would create significant disruption, especially given its central role in current membrane systems.</p><h4><strong>Funding, Student Training, and the Academic Mission</strong></h4><p>The final part of the discussion turns to the academic research environment itself. Stephen emphasizes that the most important responsibility of his laboratory is not simply generating new membrane concepts, but training students and ensuring that they can complete their degrees in a supportive research environment.</p><p>Funding uncertainty directly affects that mission. Reduced proposal success rates make it harder to maintain the number of graduate students needed for a healthy research group. This has implications beyond immediate staffing. Laboratories function best when experienced students train newer members, creating continuity in methods, culture, and technical knowledge. If groups shrink too far, that continuity is lost.</p><p>He views graduate research as both education and work experience. Students are not only learning theory; they are learning how to think as researchers, solve open-ended problems, and contribute to technologies that may eventually benefit industry. From that perspective, sustaining student support is one of the most important parts of maintaining a strong academic research ecosystem.</p><h4><strong>Conclusion</strong></h4><p>Stephen presents membrane science as a field that sits at the intersection of chemical engineering, separation science, and analytical chemistry. Membranes are already deeply integrated into both industrial treatment and laboratory workflows, but their future depends on continued progress in selectivity, sustainability, and manufacturability.</p><p>At the same time, the discussion makes clear that technical performance alone is not enough. For membrane technologies to move from the laboratory to practice, they must be scalable, economically realistic, and supported by strong analytical validation. Academic laboratories can provide the foundational science and early demonstrations, but broader adoption depends on partnerships, funding, and translational effort.</p><p>Perhaps most importantly, the conversation highlights that advances in membrane science are inseparable from the students and researchers who carry them forward. In that sense, the future of separations depends not only on materials and methods, but also on sustaining the people who develop them.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

Selective Separations: What Membrane Science Can Teach Chromatographers

<p><strong>This study introduces LCMS-Net, a deep learning model designed for direct analysis of raw LC-HRMS data without the need for manual preprocessing. By modeling spatial features of the data, the approach improves reproducibility and detection performance in untargeted metabolomics workflows.</strong></p><p>LCMS-Net demonstrated improved performance in forensic cause-of-death screening and colon cancer detection, outperforming existing methods while reducing batch effects across instruments. Its simplified architecture and lack of pretraining requirements enable faster and more efficient data analysis, highlighting its potential for routine metabolomics and forensic applications.</p><blockquote><h4><strong>The original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05404"><strong>LCMS-Net: Deep Learning for Raw High Resolution Mass Spectrometry Data Applied to Forensic Cause-of-Death Screening</strong></a></h4><p>Lisa M. Menacher, Liam J. Ward, Fredrik Heintz, Henrik Green, and Oleg Sysoev*</p><p>Anal. Chem. 2026, 98, 9, 6589–6597</p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05404">https://doi.org/10.1021/acs.analchem.5c05404</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><p><strong>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.</strong></p><div><p>Metabolomics is the study of all low-molecular-weight substances in a biological specimen. <a href="javascript:void(0);">(1)</a> As this is closely linked to cellular functions and biochemical processes, it offers a comprehensive view of the current physiological state of an organism. This makes metabolomics a promising tool for a broad range of applications, including diagnostics, precision medicine, and toxicology. <a href="javascript:void(0);">(1−3)</a> However, large-scale large-scale liquid chromatography-high resolution mass spectrometry (LC-HRMS) studies are difficult due to the complex and labor-intensive data preprocessing. This typically involves peak picking, peak alignment, gap filling, and normalization, to simplify the data structure, extract biologically relevant features, and improve the interpretability for subsequent analyses. <a href="javascript:void(0);">(4−7)</a> Although tools like XCMS or MZmine offer widely used implementations of this workflow, the preprocessing of LC-HRMS data remains challenging, for a number of reasons: (1) The preprocessing of LC-HRMS data can be time-consuming due to computational constraints for large datasets. <a href="javascript:void(0);">(4,8,9)</a> (2) Domain knowledge is necessary to select suitable parameters for the used preprocessing software, and thus to obtain reliable features. <a href="javascript:void(0);">(4,7,8)</a> (3) The reproducibility of the extracted features is often limited across software libraries, especially for low-abundant metabolites. <a href="javascript:void(0);">(4,8)</a> (4) Preprocessing tools may fail to detect some metabolites entirely, resulting in the loss of potentially important information. <a href="javascript:void(0);">(4)</a></p><p>In the past few years, deep learning models have emerged as promising alternatives to the traditional preprocessing workflow for LC-HRMS data. While many publications in this field have been focused on enhancing a particular step of the preprocessing, such as peak identification or peak alignment, end-to-end deep learning has also gained popularity. <a href="javascript:void(0);">(9,10)</a> In end-to-end deep learning, a model is trained to extract useful information directly from raw data without explicit feature engineering. Often, this is less time-consuming than conventional methods and improves the predictive accuracy of the downstream task. This was demonstrated by Cadow et al., who converted raw MS data from prostate biopsies into pseudoimages through binning. They then applied pretrained deep learning models for image processing to extract feature vectors from the pseudoimages and trained a classifier to discriminate between tumor and healthy cases. <a href="javascript:void(0);">(11)</a> A similar approach was also used by Shen et al. to predict the gestational age of pregnant women. To address data scarcity, they proposed a data augmentation strategy that simulates retention time (RT) drifts during the data acquisition. As a result, several pseudoimages can be produced from a single LC-HRMS sample, which substantially increases the size of the training set. <a href="javascript:void(0);">(12)</a> Furthermore, Wang et al. developed an end-to-end deep learning model to detect esophageal squamous cell carcinoma based on raw LC-HRMS data. By decomposing a sample into multiple tiles instead of just one down-scaled pseudoimage, their approach preserves more details of the raw LC-HRMS data. <a href="javascript:void(0);">(13)</a> Most recently, Deng et al. used an ensemble of pretrained image classification models for lung cancer detection. Their approach enables more robust predictions for multiclass classification tasks. Furthermore, model explainability was addressed through the analysis of contributing factors. <a href="javascript:void(0);">(14)</a> Although, these studies collectively highlight the potential of end-to-end deep learning for metabolomics-based analyses, they also show its limitations. For example, the use of pretrained architectures for image classification may be flawed due to the substantially different topology of LC-HRMS data and natural images. Natural images typically contain hierarchically structured objects with geometrical properties such as size or patterns while objects in LC-HRMS pseudoimages are essentially represented as one-dimensional peaks along the retention time axis and are sharply localized in <i>m</i>/<i>z</i>-value. <a href="javascript:void(0);">(6,15)</a> Existing deep learning methods for metabolomics primarily use 2D-convolutions and thus do not take into account such spatial properties of LC-HRMS data. Consequently, there remains a need for more robust methods that are specifically tailored to LC-HRMS data. This is particularly relevant for real-world applications, where batch effects and diverse study populations are common and difficult to mitigate.</p><p>This study presents LCMS-Net, a fully automated end-to-end deep learning model for the analysis of LC-HRMS data. By directly processing the raw data and taking into account its spatial properties by using 1D-convolutions, LCMS-Net mitigates the need for time-intensive, manual feature engineering and improves the classification performance of downstream tasks. This is demonstrated through comprehensive benchmarking for two different applications, forensic CoD screening and colon cancer detection. To the best of our knowledge, it is the first time end-to-end deep learning is applied to post-mortem metabolomics and in the context of forensic science. Furthermore, LCMS-Net achieves robust results even in the presence of severe batch effects, as shown by training and evaluating the CoD screening model with data from different measurement instruments. Lastly, LCMS-Net does not rely on large pretrained deep learning models, and thus requires less computational resources than previous end-to-end learning approaches for the analysis of LC-HRMS data.</p><h4><strong>Methods</strong></h4><h5><strong>Cause-of-Death Screening Dataset</strong></h5><p>The cause-of-death screening study was approved by the Swedish Ethical Review Authority (Dnr 2019–04530 &amp; Dnr 2025–0249–02). All samples were collected from autopsy cases admitted to the Swedish National Board of Forensic Medicine between July 2017 and December 2024, which had undergone routine toxicological screening via HRMS. Screening was performed from femoral whole blood samples, in accordance with standardized procedures reported previously. <a href="javascript:void(0);">(32)</a> Sample separation was performed using gradient elution on a C18 column (150 mm × 2.1 mm, 1.8 μm; <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1952"><strong>Waters Acquity HSS T3 column</strong></a>, Water Sverige AB, Sweden). MS-data was collected in positive mode and the total acquisition time for each sample was 12 min. Samples admitted between July 2017 and November 2020 were run using an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=6540+Q-TOF"><strong>Agilent 6540 Q-TOF system</strong></a> in MS-mode only, and samples admitted afterward using an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=6546+Q-TOF"><strong>Agilent 6546 Q-TOF system</strong></a> with data-dependent acquisition mode (autoMSMS). Aside from these differences in acquisition strategy, source settings and TOF parameters (e.g., gas temperatures, voltages, and mass ranges) were kept consistent between platforms. Henceforth, we will refer to the former as <i>Dataset A</i> and the latter as <i>Dataset B</i> for clarity.</p><p>Dataset A was primarily used for the implementation and evaluation of LCMS-Net and includes 4282 autopsy cases processed in over 641 analytical runs. All cases belong to one of the following five CoD groups: acidosis (<i>n</i> = 100), drug intoxication (<i>n</i> = 1385), ischemic heart disease (IHD) (<i>n</i> = 1362), hanging (<i>n</i> = 1200), and pneumonia (<i>n</i> = 235). A detail summary of the inclusion criteria and study population was previously described by Ward et al. <a href="javascript:void(0);">(26)</a> Dataset B was used to evaluate the sensitivity of LCMS-Net to batch effects and includes additional 5485 autopsy cases with the same inclusion criteria and CoD groups as Dataset A.</p><h4><strong>Overview of LCMS-Net</strong></h4><p>LCMS-Net is a end-to-end deep learning model for the analysis of raw LC-HRMS data. First, a data preparation pipeline transforms the raw LC-HRMS data into pseudoimages. Afterward, convolutional neural networks (CNNs) specifically designed to take the spatial properties of LC-HRMS data into account are used to extract relevant features for the downstream task. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05404#fig1">Figure 1</a> shows an overview of this workflow for CoD screening, as well as the architecture of LCMS-Net.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_9_6589_6597_Figure_1_Overview_of_LCMS_Net_applied_to_Co_D_screening_6db285c40d.jpg" alt="Anal. Chem. 2026, 98, 9, 6589–6597: Figure 1. Overview of LCMS-Net applied to CoD screening. Binning is used to reduce the size of the raw LC-HRMS data and to ensure equally shaped input matrices. Afterward, the input matrices are processed by an ensemble of 1D-CNNs consisting of a depthwise 1D convolutional layer, followed by max pooling and spatial dropout. The results of the CNNs are flattened and dense layers are used to predict the class labels of the input data." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_9_6589_6597_Figure_1_Overview_of_LCMS_Net_applied_to_Co_D_screening_6db285c40d.jpg 238w," sizes="100vw" width="1500" height="986"></p><h4><strong>Results and Discussion</strong></h4><h5><strong>Evaluation of Prediction Performance for CoD Screening</strong></h5><p>First, LCMS-Net was evaluated on the CoD screening dataset (Dataset A). <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05404#fig2">Figure 2</a> shows the results of the model comparison for the CoD screening dataset. With an average accuracy of 70.8%, LCMS-Net outperformed all four benchmark models trained on preprocessed LC-HRMS data. In comparison, our previously published OPLS-DA model for CoD screening achieved only 65.0% accuracy (<i>p</i>-value = 0.0010). Furthermore, LCMS-Net also achieved a better F1-score and sensitivity than these models, while maintaining a high specificity score. The deep learning benchmark model, DeepMSProfiler, achieved a similar accuracy to LCMS-Net. However, LCMS-Net outperformed DeepMSProfiler in terms of both F1-score (<i>p</i>-value = 0.0122) and sensitivity (<i>p</i>-value = 0.0010). This indicates that our method maintains a better balance between true positives and false positives across the five CoD groups, which is especially important for high-stakes applications like forensic science. It should be noted that traditional cross-validation was used for the estimation of p-values, as our purpose was to compare models with fixed hyperparameters. When instead comparing frameworks (e.g., RF vs SVM), nested cross-validation would be more appropriate.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_9_6589_6597_Figure_2_Evaluation_of_Co_D_screening_prediction_performance_of_LCMS_Net_in_comparison_to_benchmark_models_11eef68bb7.jpg" alt="Anal. Chem. 2026, 98, 9, 6589–6597: Figure 2. Evaluation of CoD screening prediction performance of LCMS-Net in comparison to benchmark models. The prediction performance of a classifier is measured by accuracy, macro F1-score, macro sensitivity, and macro specificity over five model runs. The error bars represent the standard deviations between model runs." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_9_6589_6597_Figure_2_Evaluation_of_Co_D_screening_prediction_performance_of_LCMS_Net_in_comparison_to_benchmark_models_11eef68bb7.jpg 245w," sizes="100vw" width="1500" height="709"></p><p>Notably, LCMS-Net achieves its high classification performance without pretraining on natural images. This shows that although transfer learning is often useful, it may fail if the source (e.g., natural images) and target data distribution (e.g., LC-HRMS data) are too different. Such domain mismatch can lead to negative transfer, where features from a pretrained model negatively impact the classification performance of the downstream task, resulting in a lower accuracy than training a simpler model from scratch. <a href="javascript:void(0);">(42)</a> By employing an architecture tailored to LC-HRMS data, LCMS-Net is also computationally more efficient, with fewer than 500,000 trainable parameters compared to over 7 million trainable parameters in DeepMSProfiler. <a href="javascript:void(0);">(14)</a> This makes our method accessible to researchers with limited computational resources.</p><h5><strong>Application for Colon Cancer Detection</strong></h5><p>Lastly, we have tested the potential of LCMS-Net in another application domain, by assessing its prediction performance on the CRC dataset. The cancer detection task has been previously used by Deng et al. to show that DeepMSProfiler can be successfully applied to different application areas, making it a suitable benchmark task. We trained a separate instance of LCMS-Net for the model evaluation on the CRC dataset due to differences in sample preparation, analytical protocols, and instrument setup compared to the CoD screening dataset. The hyperparameter settings remained unchanged, as we assumed similar structural properties for both datasets.</p><p>LCMS-Net outperforms DeepMSProfiler with an F1-score of 97.3% compared to 95.5% on the colon cancer detection task. Furthermore, sensitivity and specificity improvements of 2.8% were observed. These results underline the relevance of LCMS-Net for other application areas than CoD screening. A detailed overview of the evaluation metrics for the colon cancer prediction can be found in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05404/suppl_file/ac5c05404_si_001.pdf">Supporting Table 7</a>.</p><h4><strong>Conclusion</strong></h4><p>Current preprocessing workflows for untargeted metabolomics are often time-consuming, require extensive domain knowledge, lack reproducibility, or fail to detect some metabolites entirely. LCMS-Net offers an alternative end-to-end approach by operating directly on the raw LC-HRMS data and explicitly modeling its spatial properties. The deep learning model enables faster processing and does not require manual parameter selection. Furthermore, it has been shown through two case studies, CoD screening and cancer detection, that our method extracts a higher amount of relevant information from the raw data and thus outperforms existing models for the analysis of metabolomics data. Specifically, LCMS-Net achieves an average F1-score of 65.5% for CoD screening and 97.3% for colon cancer detection. The previous state-of-the-art models achieved 56.1% (OPLS-DA) and 95.5% (DeepMSProfiler) respectively. The prediction performance of LCMS-Net is consistent even when applied to data from different measurement instruments than those used for the training of the deep learning model, showing its robustness toward batch effects. However, the interpretability of LCMS-Net remains limited and future development is needed to assess which metabolites are learned by the model and which remain undetected. Despite this, LCMS-Net opens up new opportunities for large-scale analyses of LC-HRMS data, potentially driving innovation across numerous application domains.</p></div>

LCMS-Net: Deep Learning for Raw High Resolution Mass Spectrometry Data Applied to Forensic Cause-of-Death Screening

<p><strong>In the week of April 20, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars"><strong>👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</strong></a></h4><p><strong>👉 Search and filter in the largest global database</strong> with over <strong>5 500 GC, LC, MS and spectroscopy webinars</strong>.</p></blockquote><h5><strong>1. Metrohm: Copper deposition baths: Advanced analytical solutions for development and monitoring</strong></h5><ul><li>Tu, 21.4.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6123">Registration</a></li></ul><p>Discover a multi-method approach to copper plating bath analysis combining titration, CVS, XRF, and pH measurement for improved process control, data reliability, and production quality.</p><h5><strong>2. Bruker: Exploring the Caenorhabditis elegans lipidome in 4D</strong></h5><ul><li>Tu, 21.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6106">Registration</a></li></ul><p>Combining chromatography, trapped ion mobility, accurate mass and fragment information enables confident discovery and annotation of novel lipids in this key model organism.</p><h5><strong>3. Technology Networks: Episode 3: PFAS in Food – Addressing Contamination in the Food Supply Chain</strong></h5><ul><li>Tu, 21.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6108">Registration</a></li></ul><p>PFAS contamination in food is an emerging analytical and regulatory challenge, especially as testing expands beyond water into complex food and animal protein matrices.</p><h5><strong>4. Agilent Technologies: Getting the Most from Your Agilent LCMS System</strong></h5><ul><li>Tu, 21.4.2026 17:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5740">Registration</a></li></ul><p>In this webinar, we will discuss best practices and preventative maintenance tips to help maximize your instrument’s uptime.</p><h5><strong>5. Thermo Fisher Scientific: Mass spectrometry strategies to power drug discovery</strong></h5><ul><li>Tu, 21.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6097">Registration</a></li></ul><p>In this first master class session, explore how advanced mass spectrometry strategies are powering the next generation of drug discovery through chemoproteomics.</p><h5><strong>6. SCIEX: PFAS first steps: A roundtable for new analysts</strong></h5><ul><li>We, 22.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6103">Registration</a></li></ul><p>PFAS roundtable webinar for new analysts covering troubleshooting, workflow optimization, and regulatory readiness with expert insights from LC-MS specialists and industry professionals.</p><h5><strong>7. SelectScience: What’s in your hydrogen? Analytical toolkits for fuel purity analysis</strong></h5><ul><li>We, 22.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6055">Registration</a></li></ul><p>Join this dual-session webinar on hydrogen impurity testing and ISO 14687 fuel quality. Learn how GC, GC-MS, IC, and FTIR workflows support safe, compliant hydrogen production and fuel-cell applications.</p><h5><strong>8. Separation Science: Testing PFAS in Biosolids: From Sample Preparation to Interference Separation</strong></h5><ul><li>We, 22.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6124">Registration</a></li></ul><p>Learn how robust analytical approaches can deliver confident results, even in the most challenging wastewater and biosolid samples.</p><h5><strong>9. Thermo Fisher Scientific: Automated direct mRNA sequence mapping using online partial RNase T1 digestion and 2D LC-MS</strong></h5><ul><li>We, 22.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6110">Registration</a></li></ul><p>This webinar highlights a fully automated 2D LC-MS workflow for rapid, high-coverage mRNA characterization.</p><h5><strong>10. SCIEX: Unlocking SCIEX OS software: automating acquisition, analysis, and 21 CFR part 11 compliance reporting</strong></h5><ul><li>We, 22.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6125">Registration</a></li></ul><p>Join us to discover how the powerful capabilities of SCIEX OS Software help laboratories improve efficiency, reduce manual steps, and maintain data integrity.</p><h5><strong>11. Thermo Fisher Scientific: From experts to applications: Screening protein-drug interactions with HT-PELSA</strong></h5><ul><li>We, 22.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6098">Registration</a></li></ul><p>Part 2 of the Chemoproteomics Master Class explores HT-PELSA with Orbitrap Astral MS, showing peptide-level ligand binding analysis for target discovery, specificity, and drug pipeline insights.</p><h5><strong>12. Agilent Technologies: Pesticide Residues &amp; Fumigants Edition</strong></h5><ul><li>Th, 23.4.2026 08:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5955">Registration</a></li></ul><p>Food Safety Webinar Series – Part 2: Pesticide Residues &amp; Fumigants Edition. Explore LC-MS/MS and GC-MS/MS workflows, QuEChERS extraction, and regulatory reporting under Codex and EU frameworks.</p><h5><strong>13. Agilent Technologies: Enhancing Peptide and Oligonucleotide Analysis with Ultra Inert HPLC Technology</strong></h5><ul><li>Th, 23.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6134">Registration</a></li></ul><p>Learn how ultra-inert HPLC columns improve LC analysis of peptides and oligonucleotides by minimizing metal interactions and enhancing peak shape, sensitivity, and reproducibility.</p><h5><strong>14. Thermo Fisher Scientific: Chromeleon Admin Console III: Data management and automation</strong></h5><ul><li>Th, 23.4.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6126">Registration</a></li></ul><p>In this practical session, we’ll dive into more Administration Console capabilities that help you manage and standardize your setup at scale.</p><h5><strong>15. Waters Corporation: Informatics series #31 Empower Advanced Custom Fields - Examples</strong></h5><ul><li>Th, 23.4.2026 11:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5923">Registration</a></li></ul><p>Learn how to use Advanced Custom Fields in Empower to streamline calculations, improve reporting, and ensure validation-ready, compliant data processing.</p><h5><strong>16. Waters Corporation: A Multi-Residue Approach - Pesticides, Pharmaceuticals, and Personal Care Products</strong></h5><ul><li>Th, 23.4.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6112">Registration</a></li></ul><p>Navigating challenges and opportunities for environmental testing labs under the revised EU Water Framework Directive.</p><h5><strong>17. Waters Corporation: Analysis of Glyphosate, Glyphosinate and AMPA in water without the need of derivatisation</strong></h5><ul><li>Th, 23.4.2026 15:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5926">Registration</a></li></ul><p>Learn about required method conditions and instrumentation for Glyphosate, Glyphosinate and AMPA analysis in water without the need of derivatisation.</p><h5><strong>18. Thermo Fisher Scientific: Insights from an IC specialist: Are you using the right eluent?</strong></h5><ul><li>Th, 23.4.2026 16:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6127">Registration</a></li></ul><p>Join the IC Ask the Experts session to learn practical eluent management strategies, optimize ion chromatography workflows, and get answers to your real-world analytical challenges.</p><h5><strong>19. Waters Corporation: Managing Process Performance in Stage 3 Process Validation: Regulatory Expectations for Continued Process Verification</strong></h5><ul><li>Th, 23.4.2026 17:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6060">Registration</a></li></ul><p>Join this webinar to gain practical insights into regulatory expectations for CPV and strengthen your approach to maintaining process performance throughout the product lifecycle.</p><h5><strong>20. Thermo Fisher Scientific: High-throughput activity based protein profiling - Systematic mapping of covalent drug-protein interactions on a proteome-wide scale</strong></h5><ul><li>Th, 23.4.2026 19:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6099">Registration</a></li></ul><p>Part 3 of the Chemoproteomics Master Class highlights activity-based proteome profiling and covalent screening to accelerate target identification and drug discovery using scalable MS workflows.</p><h5><strong>21. Agilent Technologies: Advancing and Characterizing Next-Gen Antibody Conjugates: Insights from BBB-Targeting Antibody Platforms</strong></h5><ul><li>Fr, 24.4.2026 08:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6128">Registration</a></li></ul><p>Discover next-generation antibody therapeutics, BBB-targeting platforms, and LC-QTOF workflows for advanced characterization of complex antibody-drug and oligonucleotide conjugates.</p>

Webinars LabRulezLCMS Week 17/2026

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

The Analytical Scientist

Bruker

Wiley

SCIEX

Evosep Biosystems

Waters Corporation

<p><strong>This online event has been designed for our customers and brings together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Use of LC-MS in process analytical testing as part of development of a continuous manufacturing workflow</strong></h5>
<ul>
<li>Daniel Myatt / Ronan Gough, CPI</li>
</ul>
<h5><strong>10:35–11:00 Tips and tricks for biotherapeutics characterization by peptide mapping</strong></h5>
<ul>
<li>Giulia Calloni, SCIEX</li>
</ul>
<h5><strong>11:00–11:25 Developing methods for SEC-MS and IEX-MS for the analysis of biotherapeutics</strong></h5>
<ul>
<li>Sarah Nguyen, Strasbourg University</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 The power of CZE analysis for characterization of NANOBODY® molecules</strong></h5>
<ul>
<li>Dries Dejaegere, Sanofi</li>
</ul>
<h5><strong>12:00–12:25 Multi-capillary gel electrophoresis to increase throughput for the purity analysis of biotherapeutic proteins</strong></h5>
<ul>
<li>Theresa Merlino, The Janssen Pharmaceutical Companies of Johnson &amp; Johnson</li>
</ul>
<h5><strong>12:25–12:50 A disruptive approach to the characterization of mAb charge variants during biopharmaceutical process development</strong></h5>
<ul>
<li>Greg Adams, FUJIFILM</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_1_6818ee0331/SCIEX-agenda-day-1.jpg" alt="SCIEX - agenda day 1.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 1 - Gene therapy, vaccines and oligonucleotides

SCIEX Biopharma meeting (Day 1) - Gene therapy, vaccines and oligonucleotides

Gene therapy, vaccines and oligonucleotides. The technologies presented will be CE and LC-MS.

Day 1 - Gene therapy, vaccines and oligonucleotides

<p><strong>This online event has been designed for our customers and brings  together opinion leaders, top scientists and industry innovators to share their research in the biopharma field.</strong></p>
<p>The technologies presented will be CE and LC-MS.</p>
<p>Agenda:</p>
<h5><strong>10:00–10:10 Welcome and introduction</strong></h5>
<ul>
<li>Steve Lock, SCIEX</li>
</ul>
<h5><strong>10:10–10:35 Particle seizing by CE</strong></h5>
<ul>
<li>Hervé Cottet, Montpellier University</li>
</ul>
<h5><strong>10:35–11:00 Application of CE for purity analysis in cell and gene therapy</strong></h5>
<ul>
<li>Ryan Hylands / Luiza Chrojan, Pharmaron</li>
</ul>
<h5><strong>11:00–11:25 Tips and tricks for success in CE analysis</strong></h5>
<ul>
<li>Whitney Smith, SCIEX</li>
</ul>
<h5><strong>11:25–11:35</strong> Break</h5>
<h5><strong>11:35–12:00 RNA payload analysis: development and analytical challenges</strong></h5>
<ul>
<li>Jérémie Parot, SINTEF Industry</li>
</ul>
<h5><strong>12:00–12:25 The use of CE for AAV analytics</strong></h5>
<ul>
<li>Padraig Flaherty, MeiraGTx</li>
</ul>
<h5><strong>12:25–12:50 Oligo analysis by LC-MS</strong></h5>
<ul>
<li>Alexandra Bushby, Labcorp</li>
</ul>
<h5><strong>12:50–13:00 Wrap-up and Q&amp;A</strong></h5>
<blockquote>
<p><strong>Presenter:</strong> Steve Lock, PhD (Snr. Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)</p>
</blockquote>
<blockquote>
<p>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p>
</blockquote>
<p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/SCIEX_agenda_day_2_b442145213/SCIEX-agenda-day-2.jpg" alt="SCIEX - agenda day 2.jpg"/></p>


SCIEX: SCIEX Biopharma meeting - 3rd edition! Day 2 - Therapeutic proteins and peptides

SCIEX Biopharma meeting (Day 2) - Therapeutic proteins and peptides

Therapeutic proteins and peptides. The technologies presented will be CE and LC-MS.

Day 2 - Therapeutic proteins and peptides

<p><strong>Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!</strong></p>
<p>Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. </p>
<p>We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. </p>
<p>Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. </p>
<p>The event will have three parts: </p>
<ul>
<li><p><strong>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).</strong></p>
</li>
<li><p><strong>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).</strong></p>
</li>
<li><p><strong>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Day Powell (Environmental Application Specialist , Agilent)</p>
</blockquote>
<blockquote>
<p>Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.</p>
</blockquote>
<blockquote>
<p>Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Marcus Chadha (EMEA Applications Specialist Manager, Agilent)<br/>Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.</p>
</blockquote>
<blockquote>
<p>In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.</p>
</blockquote>
<blockquote>
<p>He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)</p>
</blockquote>
<blockquote>
<p>Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.</p>
</blockquote>
<blockquote>
<p>His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)</p>
</blockquote>
<blockquote>
<p>Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.</p>
</blockquote>
<blockquote>
<p>Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.</p>
</blockquote>
<blockquote>
<p>She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.</p>
</blockquote>


Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5><strong>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</strong></h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5><strong>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</strong></h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</strong></h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5><strong>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</strong></h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5><strong>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</strong></h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5><strong>10:40 - 11:20 Challenges in quantification of NDSRI’s</strong></h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</strong></h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5><strong>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</strong></h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 2)

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces.</strong></p>
<p>MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: </p>
<ul>
<li>Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</li>
</ul>
<h4>Part Three – October 31st, 2023: Building an MS Imaging Facility</h4>
<p><strong>In the final session of the series, we will have a roundtable with Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) where we will discuss the steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.</strong></p>
<blockquote>
<p><strong>Presenter:</strong> Roy Martin (Principal Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Dr. LeRoy B. Martin, III is the Principal Field Marketing Manager for Biological Mass Spectrometry at Waters Corporation. His primary role is developing and promoting advanced mass spectrometry solutions in the Americas. He is also charged with evaluating and integrating new technologies and methods in collaborations and product development. Most recently, his focus has been on molecular imaging mass spectrometry and implementation of advances in ion mobility technology. Other research interests include complex mixture quantitative proteomics and structural biology using mass spectrometry. Roy received a BS in Chemistry from Davidson College and a Ph.D. in Analytical Chemistry from North Carolina State University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ryan Leib (Director of Research, Stanford University Mass Spectrometry Laboratory)</p>
</blockquote>
<blockquote>
<p>Ryan Leib is Director of Research for the Stanford University Mass Spectrometry Laboratory. Ryan received his B.S. in Biochemistry from the University of Tulsa (Tulsa, OK), with a focus on LC/MS methods development for natural products discovery. In 2010, he received his Ph.D. in Chemistry from the University of California at Berkeley investigating ionic cluster formation and energetics in Professor Evan Williams’ mass spectrometry laboratory. Prior to joining SUMS in 2014, Ryan developed mass spectrometric analyses for complex mixtures as a Project Leader at SRI International, a non-profit contract R&amp;D firm based in Silicon Valley.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: Building an MS Imaging Facility

Building an MS Imaging Facility

The steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.

<p><strong>During drug metabolite identification (Met ID) studies collision-induced dissociation (CID) is the most commonly used fragmentation technique for LC-MS experiments.</strong></p>
<p>Many conjugation metabolites are found to have multiple bonding potentials to parent drugs. It is a great challenge to locate the bonding sites by CID due to the information lost by highly selective cleavage on these bonds. </p>
<p>The novel electron-activated dissociation (EAD) is a recently developed technology on the SCIEX ZenoTOF 7600 system. From a single LC-MS/MS experiment CID and EAD data can be collected, providing information rich fragmentation spectra. The additional information can help in confident localization and identification of metabolites compared to CID alone. These fragments can be crucial to locate the metabolic modification sites, such as conjugations. </p>
<p>In this study, the application of EAD in drug metabolite profiling is explored. The efficiency in the structural elucidation of conjugation metabolites is compared with that of CID.</p>
<p>Webinar Learning Objectives:</p>
<ul>
<li><p><strong>Learn how EAD can be advantageous in confident identification and localization of drug metabolites</strong></p>
</li>
<li><p><strong>Discover the sensitivity of the Zeno trap technology in the identification of the low abundant metabolites</strong></p>
</li>
<li><p><strong>Explore the capabilities of the Molecule Profiler software in processing EAD and CID data for drug metabolite identification</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Ming Yao (Principal Scientist, CPPDB, Bristol-Myers Squibb)</p>
</blockquote>
<blockquote>
<p>Ming Yao currently works at Bristol-Myers Squibb (BMS). He received his B.Sc. from Henan University, and his M.Sc. from the Chinese Academy of Preventive Medicine China. After graduation, he worked at the Institute of Occupational Medicine as an associate professor.</p>
</blockquote>
<blockquote>
<p>As a visiting Associate Professor, he conducted research for bioactivation of chemicals at Merck as well as the University of Western Ontario. After then, he joined BMS and he was responsible for designing and conducting in vitro and in vivo biotransformation studies for multiple programs to support both development and discovery projects. Most recently, he has also been involved in the development of protein drugs, such as the antibody drug conjugates (ADCs) and biotransformation of biologics.</p>
</blockquote>
<blockquote>
<p>Ming has over 28 years of experiences in the pharmaceutical industry and has over 50 publications and 5 book chapters covering new technologies of mass spectrometry and its applications in drug metabolism.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Rahul Baghla (Manager Pharma Applications, SCIEX)</p>
</blockquote>
<blockquote>
<p>Rahul Baghla, Manager Pharma Applications is a research scientist with 12+ years of experience in various applications of mass spectrometry delivering in Pharma/Biopharma/CRO industries. He is specialised in implementing new mass spectrometry technologies in bioanalytical/analytical method development/validation, drug discovery, ADME assays and clinical studies.</p>
</blockquote>
<blockquote>
<p>He has supported various functions within pharma industry including nutrition, wellness, and oral care based clinical trial studies over the years. Rahul has master’s degree in pharmaceutical analysis, master’s in business administration and a professional diploma in clinical research.</p>
</blockquote>
<blockquote>
<p>He is responsible for continuous engagement with pharmaceutical community to identify major analytical challenges, provide solutions and to find significant analytical opportunities for SCIEX.</p>
</blockquote>


SCIEX: Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Learn how EAD can be advantageous in confident identification and localization of drug metabolites.

LC/MS EAD & drug metabolites & localization of metabolism

<p><strong>Over the last few years, spatial biology has refined the understanding of coordinated biological processes that govern how systems both thrive and become vulnerable to disease.</strong></p>
<p>The latest tools offer advanced images that track the location and types of proteins and RNA across tissue microdomains and cellular phenotypes using a variety of detection techniques but lack the ability to see other post-transcriptional processes defined by metabolites and glycans. MALDI Imaging is a true multiomics technique that allows for spatial determination of metabolites and lipids in tissue, as well as expanding targeted analysis to small molecules, glycans, and proteins. The addition of MALDI-2 and microGRID technology enables imaging for maximum biological information at previously unreachable sensitivity and robust (sub)cellular resolution.</p>
<p>This webinar will introduce how Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue, while providing thousands of untargeted molecular images that enable deeper tissue subtyping. The combination of protein spatial localization combined with metabolites and glycans offers a new pathway for coordinated biomarker discovery to complement existing spatial techniques.</p>
<p>What to expect?</p>
<ul>
<li><strong>Live presentation from Bruker’s experts to see ease of use of the timsTOF fleX platform, new MALDI HiPLEX-IHC workflows and highlighting user stories, including focus on improved spatial resolution with microGRID, improved sensitivity with MALDI-2, improved separation selectivity with trapped ion mobility and comprehensive software solutions</strong></li>
</ul>
<p>Who should attend?</p>
<ul>
<li><p>Anyone using or interested in using tools for spatial biology discovery or translation</p>
</li>
<li><p>Scientists &amp; researchers interested in expanding their workflows to the spatial dimension, scientists working with spatial distribution of small molecule biologics</p>
</li>
<li><p>MALDI Imaging users wanting to expand their workflows</p>
</li>
<li><p>Anyone interested in learning more about MALDI Imaging capabilities</p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Kate Stumpo, Ph.D. (Senior Market Manager Imaging, Bruker, Billerica, MA, USA)</p>
<ul>
<li>Introduction and welcome to MALDI Imaging </li>
<li>Spatial biology meets Mass Spectrometry in cancer research </li>
<li>MALDI Imaging utility in neurological research</li>
</ul>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Corinna Henkel, Ph.D. (Application Scientist Imaging, Bruker, Bremen, Germany)</p>
<ul>
<li>MALDI HiPLEX-IHC workflow technical introduction</li>
<li>Software solutions for multiomics integration</li>
</ul>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Bjoern Wendik, Ph.D. (Business Development Manager, Bruker, Bremen, Germany)</p>
<ul>
<li>Bridging non-MS imaging to the MALDI world</li>
<li>Automation, workflow and relevance for future clinical applications</li>
</ul>
</blockquote>


Bruker: Redefining Hiplexed Spatial Multiomics

Redefining Hiplexed Spatial Multiomics

How Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue.

<p><strong>This webinar is your guide to get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.</strong></p>
<p>Utilize protein aggregation capture (PAC) on magnetic microparticles in an end-to-end  standardized and hands-off workflow, starting from protein lysate or plasma to peptide loaded on Evotips.</p>
<h4>Why choose an automated workflow?</h4>
<p>Automated sample preparation workflows have become a popular tool in proteomics laboratories for a number of reasons. With increased sample throughput on the Evosep One, you can prioritize numerous technical and biological replicates, adding robustness to downstream bioinformatic analyses.</p>
<p>By adopting full automation, you can gain precise control over protocols, ensuring reproducibility across samples and experiments. This minimizes batch effects, resulting in more reliable data for analysis and interpretation.</p>
<p>Furthermore, enhanced automation significantly reduces manual labor, enhancing reproducibility and providing researchers with more time for critical decision-making. This workflow also proves cost-efficient for large-scale applications, optimizing protein input for digestion.</p>
<h4>AUTOMATED WORKFLOW FOR INTEGRATED SAMPLE DIGESTION AND EVOTIP LOADING FOR HIGH-THROUGHPUT CLINICAL PROTEOMICS</h4>
<blockquote>
<p><strong>Presenter:</strong> Anders H.Kverneland (MD &amp; Postdoctoral researcher at Center for Cancer Immune Therapy, Herlev hospital)</p>
</blockquote>
<p>Protein identification and quantification is an important tool for biomarker discovery. With the increased sensitivity and shortened the analysis tim​e of modern mass spectrometers, sample-preparation remains a bottleneck and source of variability when studying large cohorts. To address this issue, we evaluated the use of a simple integrated workflow on the Opentrons OT-2 robot enabling both sample digestion and Evotip loading. Our results demonstrate high sensitivity combined with both reproducibility and stability even with very low sample inputs. The integration of the digestion and Evotip loading also strongly reduced the amount of reagents needed for the sample preparation. Using the integrated workflow, we evaluate the effects of cancer immune therapy on the plasma proteome in metastatic melanoma patients.</p>
<h4>STANDARDIZED AND FULLY AUTOMATED DEEP PROTEOME PROFILING OF PLASMA INTEGRATED WITH EVOSEP ONE ENABLES LARGE-SCALE CLINICAL COHORT ANALYSIS</h4>
<blockquote>
<p><strong>Presenter:</strong> Dorte Becker-Jensen (Application Manager at Evosep)</p>
</blockquote>
<p>This streamlined end-to-end workflow enables deep plasma profiling through the automated enrichment of membrane-bound vesicles and depletion of abundant proteins from a mere 4 μl of plasma. Integrated with the SCIEX ZenoTOF, it consistently identifies more than 3,500 protein groups, all with the ease of processing 30 samples per day at the push of a button.</p>


Evosep: Elevate efficiency: The power of automation

Elevate efficiency: The power of automation

Get started with a fast and efficient, automated sample preparation protocol on the Opentrons OT-2.

<p><strong>In this webinar, we will present end-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.</strong></p>
<p>A broad portfolio in sample prep automation for protein therapeutics allows for highly reproducible results in the starting point of the analysis. A broad range of consumables and columns will be presented, leading into the subsequent separation via HPLC and detection by mass spectrometry.</p>
<p>The 6545XT AdvanceBio was particularly developed for intact protein analysis, and the ultra-high vacuum and large molecule autotune led to excellent sensitivity in denatured and native applications, allowing quantitation on the intact protein level as well as ADR calculations. Peptide mapping and glycan analysis results, along with the confirmation of oligonucleotide sequences using Q-TOF-based workflows, will be presented.</p>
<p>We will also highlight the ultrahigh performance of the novel 6495 triple quadrupole LC/MS system (G6495D) with MassHunter Workstation 12.1 for comprehensive multiplexed protein quantification. Artificial intelligence (AI)-based SWARM autotune and enhanced system features provide seamless protein quantification method optimization, ultimate analytical sensitivity, and high analytical precision as well as user-friendly instrument care and maintenance.</p>
<p>Lastly, we will show results from oligonucleotides and proteins analyzed on LC/MS single quadrupole and Time of Flight (TOF) instruments, the latest scientific applications, and recent method improvements.</p>
<blockquote>
<p><strong>Presenter:</strong> Ian Edwards, Ph.D. (LC/TQ Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Ian holds a PhD from the Centre for Proteome Research at the University of Liverpool. He has spent time as a pre- and post-sales MS applications specialist focused on MS imaging and proteomics, as a field marketing manager for -omics, and as a global pharmaceutical marketing manager. Ian joined Agilent recently as LC/TQ Product Manager.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Russell Burge, Ph.D. (LC/SQ and LC/TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>Russell earned a PhD in biochemistry and molecular biology from Scripps Research. He has extensive experience in the R&amp;D of biomolecules and biopharmaceuticals, and the implementation of automated workflows. Russell has acted as a Product Manager for various products in Life Science and Industrial Markets, and he currently manages the LC/MS SQ and LC/MS TOF product portfolios at Agilent.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Christian Klein, Ph.D. (LC/Q-TOF Portfolio Product Manager, Agilent Technologies Inc.)</p>
</blockquote>
<blockquote>
<p>With an education in Chemistry, Chris Klein received his Ph.D. in 2005 at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He joined Agilent Technologies in 2010 as the lead chemist in the LC/Q-TOF R&amp;D team. In 2018 Chris jointed the marketing team as Portfolio Product Manager, responsible for LC/Q-TOF and Ion Mobility.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Róisín Murtagh (Editor, Wiley)</p>
</blockquote>
<blockquote>
<p>Róisín Murtagh has been an editor for Wiley Analytical Science since 2021. She holds a science degree from Maynooth University, Ireland, and an MSc in Medicinal Chemistry from the Open University, UK. With a background encompassing over 10 years of experience in analytical science, she has actively contributed to both industry and academic research.</p>
</blockquote>


Wiley: Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

Intelligent LC/MS tools for quantitation and characterization of biopharmaceuticals

End-to-end solutions for biopharma lab workflows with a focus on multiple mass spectrometry- based analysis techniques, ranging from SQ, TQ, TOF and Q-TOF.**

LCMS webinars focusing on LC/TOF - page 21